Analysis of care in a routine clinical practice setting show that 40-week treatment of biologic dupilumab (Dupixent, Sanofi-Regeneron) plus noncosmetic topical moisturizer (emollient) is associated with significantly improved symptoms and health-related quality of life (HRQoL) in particular patients with atopic dermatitis (AD).

In a new study presented at the American Academy of Dermatology (AAD) 2019 Annual Meeting in Washington, DC, this week, a team of investigators from the Aragon Psychodermatology Research Group, of the Dermatology Derpartment at Royo Villanova Hospital in Spain, showed that subcutaneous dupilumab was significantly beneficial in 11 patients with chronic AD who had an inadequate response to topic and systemic treatment 6 months prior to trial selection.
 
Dupilumab Improved Outcomes in Patients With Chronic Rhinosinusitis, Nasal Polyps

Patients were additionally treated with emollients and preventive artificial tears during the treatment period.

Dupilumab—approved in the United States for the treatment of AD and corticosteroid-dependent or eosinophilic asthma in patients aged 12 years or older—is a monoclonal antibody touted for its mechanism of blocking interleukin (IL) pathways integral to various inflammatory diseases. According to Sanofi-Regeneron, it is currently being investigated for the treatment of asthma, eosinophilic esophagitis, food allergy, chronic rhinosinusitis, and other respiratory and dermatological conditions.

A version of this article was originally published by MD Magazine. View the full article at MdMag.com.